Figure 4.
Reduced ELOVL2 gene expression is associated with a more malignant phenotype in breast cancer. (A) ELOVL2 gene expression in different types of breast cancer cell lines. The analysis was performed using the previous microarray datasets, which consisted of 51 breast cancer cell lines (44). *P < 0.05, determined by Wilcoxon rank-sum test. (B) ELOVL2 gene expression in patients with basal and non-basal like breast cancer types. The P-value was determined by Welch's test. (C) ELOVL2 gene expression in patients with different grades of breast cancer from the Scarff-Bloom-Richardson grading system. The P-value was determined by Dunnett-Tukey-Kramer's test. ELOVL2 gene expression-dependent Kaplan-Meier survival estimate of (D) metastasis-relapse (MR) free survival in breast cancer patients. (E) Worse overall survival of the patients with lower level of ELOVL2 in pan-cancer analysis.